Hylan G-F 20 | Placebo | |
N = 123 | N = 130 | |
Preferred term | n (% of patients) | n (% of patients) |
Any treatment-emergent target knee AE | 44 (35.8) | 44 (33.8) |
Any treatment and/or procedure-related target knee AE | 7 (5.7) | 4 (3.1) |
Arthralgia | 2 (1.6) | 3 (2.3) |
Joint effusion | 2 (1.6) | 0 (0) |
Arthritis | 1* (0.8) | 0 (0) |
Arthropathy | 1 (0.8) | 0 (0) |
Injection site pain | 1 (0.8) | 1 (0.8) |
Any treatment-related target knee AE | 4 (3.3) | 1 (0.8) |
Any procedure-related target knee AE | 6 (4.9) | 4 (3.1) |
Related to treatment refers to unknown relationship to, or possibly, probably, or definitely related to treatment. Patients are counted once for each unique adverse event (AE) and may have had more than one unique AE. If a patient had more than one occurrence of the same AE, the strongest relationship to study treatment or injection procedure was included. Treatment groups reflect the actual treatment received, not the randomised treatment. Patients may be counted in more than one category. *Patient withdrew from the study due to target knee arthritis of moderate severity.